Clinical Trial Update: A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending dose trial of Bendavia (MTP-131) in heart failure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Bendavia (MTP-131)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Heart Failure | Phase 1 | Status: WITHDRAWN